DP-DCT 1.0:A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07595289

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Not applicable
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07595289
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07595289. Randomized; no masking; primary purpose other. Start 2026-08-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DP-DCT 1.0:A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform
Acronym
DP DCT
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Dapagliflozin (10mg Tab)
Intervention (Device)
Continuous Glucose Monitoring (CGM)
Intervention (Other)
Self-Monitoring of Blood Glucose (SMBG)
Lead sponsor
The Third Xiangya Hospital of Central South University (class: other)

Record details

Record id
cardio:ct-nct07595289
Content hash
efa4135e0163cef76b1943f8af9b7e3df66dd56ecd5d6d39d818c26779ea39d0